Eohilia (budesonide oral suspension)
An approved treatment for Eosinophilic Esophagitis.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Budesonide oral suspension wherever you encounter it, plus the key facts at a glance.
- Generic name
- Budesonide oral suspension
- Brand name
- Eohilia
- Development codes
- TAK-721, SHP621
- Drug class
- Corticosteroid
- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- How it's taken
- Oral suspension swallowed from a packet, twice a day for 12 weeks
A thick, cherry-flavored liquid steroid swallowed from a packet twice a day for 12 weeks to treat eosinophilic esophagitis (EoE) in people 11 and older[1].
The FDA approved Eohilia on February 9, 2024[2], and Takeda described it as the first FDA-approved oral therapy for EoE[3]. Its label says it has not been shown to be safe and effective for longer than 12 weeks[1].
We'll email you when Eohilia's FDA label changes, when the FDA acts on it, and when new trials for Eosinophilic Esophagitis open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Budesonide oral suspension fits
Eohilia (budesonide oral suspension) is a swallowed corticosteroid approved for a 12-week course in people 11 and older with eosinophilic esophagitis, and it is not labeled for use beyond 12 weeks[1].
- The 2020 AGA and Joint Task Force guideline gives its one strong recommendation to topical, swallowed steroids over no treatment, and also suggests proton pump inhibitors, elimination or elemental diets, and dilation of a narrowed esophagus in adults[9].
- Dupixent (dupilumab) is also FDA approved for eosinophilic esophagitis, as an injection under the skin labeled for people 1 and older who weigh at least 15kg[8]. Neither the Eohilia label nor the Dupixent label reports a trial comparing the 2 drugs directly.
- Anyone weighing Eohilia can ask their gastroenterologist what the plan would be after the 12 weeks end and how a biopsy would show whether it worked.
How Budesonide oral suspension works
In eosinophilic esophagitis, allergy-type immune cells called eosinophils build up in the lining of the esophagus, the tube that carries food to the stomach, which can make swallowing hard. Budesonide is a corticosteroid with a strong glucocorticoid effect and a weak mineralocorticoid effect, and its binding to the glucocorticoid receptor is about 200 times that of cortisol and 15 times that of prednisolone[1].
The label says the exact way corticosteroids work on inflammation in EoE is not known, and that they act against many of the cells and signals involved in allergic inflammation, including mast cells, eosinophils and histamine[1]. Eohilia is a thick suspension swallowed straight from the packet, and people are told not to eat or drink for 30 minutes afterward[1].
Budesonide is broken down by the liver enzyme CYP3A4, which is why drugs and grapefruit juice that block that enzyme can raise the amount reaching the bloodstream[1].
Side effects and safety
- Too much steroid and adrenal suppression. signs of excess cortisol (hypercorticism) and a drop in the body's own cortisol response can occur; extra steroid may be needed during injury, surgery or infection, and the dose may be lowered
- Infections. steroids raise the risk of viral, bacterial, fungal and parasitic infections, including chickenpox and measles, which can be serious or fatal in people who are not immune; yeast infections of the mouth, throat and esophagus occurred in trials; hepatitis B and tuberculosis can reactivate
- Erosive esophagitis. sores in the esophagus lining were found at the 12-week endoscopy in 2% on Eohilia and none on placebo
- Slower growth in children. growth is monitored in children on Eohilia, and the label's maximum treatment length is 12 weeks
- Switching from other steroids. steroid withdrawal symptoms can appear in people moving from a steroid with stronger whole-body effects, and allergies such as rhinitis or eczema may return
- Other steroid effects. monitoring for people with high blood pressure, diabetes, osteoporosis, peptic ulcer, glaucoma or cataracts
- Kaposi's sarcoma. reported with steroid use, most often for chronic conditions
- Pregnancy. based on animal studies, Eohilia may harm an unborn baby, and babies exposed to steroids before birth are watched for low adrenal function
- Signs of excess steroid or low adrenal function, more closely with moderate liver impairment
- New or worsening infections, including yeast in the mouth or throat
- New or worse heartburn or chest symptoms that could mean erosive esophagitis
- Growth in children
- Hepatitis B screening before starting
Eohilia has no boxed warning[1]. Its label warns that, like other corticosteroids, it can cause signs of excess cortisol and suppress the adrenal glands, raise the risk of infection, slow growth in children, cause withdrawal symptoms in people switching from stronger whole-body steroids, and worsen conditions such as high blood pressure and diabetes[1].
Chickenpox and measles can be serious or fatal in people on steroids who are not immune, and the label says to avoid Eohilia with fungal infections, Strongyloides threadworm infection, cerebral malaria or herpes infection of the eye[1].
In the main 12-week trial of 213 people on Eohilia and 105 on placebo, side effects in at least 2% and more common than placebo were respiratory tract infections (13% against 11%), yeast infections of the mouth, throat or esophagus (8% against 2%), headache (5% against 2%), gastroenteritis (3% against 1%), throat irritation (3% against 2%), adrenal suppression (2% against 0) and erosive esophagitis (2% against 0)[1].
Erosive esophagitis was found in 4 of 213 people at the 12-week endoscopy, and all but 1 of them were also taking a proton pump inhibitor[1]. Since approval, anaphylaxis, raised pressure around the brain and mood swings have been reported with oral budesonide products[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Budesonide oral suspension
The dose is 2mg, one 10mL packet, swallowed twice a day for 12 weeks[1]. The packet is shaken for at least 10 seconds, then squeezed from the bottom up directly into the mouth 2 to 3 times until empty, and the whole dose is swallowed[1]. Eohilia is not mixed with food or liquid. Nothing is eaten or drunk for 30 minutes afterward, then the mouth is rinsed with water and spat out without swallowing[1].
The label says to avoid grapefruit juice during treatment and to avoid CYP3A4 blockers such as ketoconazole, itraconazole, ritonavir, erythromycin and cyclosporine[1]. Eohilia is not recommended with severe liver impairment[1]. Each carton holds 60 packets, stored between 2°C and 25°C (36°F to 77°F) and never frozen[1].
Availability and cost
Only available as the brand-name product.
A 12-week course of twice-daily packets. The label gives no price, and Drugs@FDA lists no generic of this oral suspension. Takeda's copay offer covers up to $5,000 a year for eligible commercially insured patients.
Help paying for Eohilia
With private insurance, the drugmaker's copay card can lower what you pay for Eohilia. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 2 charity funds for Eosinophilic Esophagitis, 1 was open on November 16, 2026. Pick your insurance below to see which offers fit you.
- Copay help
EOHILIA Copay Offer: eligible commercially insured patients may pay as little as $0, with a maximum annual benefit of up to $5,000. Not valid for cash-paying patients or anyone covered by Medicare, Medicare Advantage, Medicaid, TRICARE, Medicare Part D, state pharmaceutical assistance programs or other government-funded plans; FEHB is not treated as government-funded. A valid prescriber ID is required, and the user must be 18 or older, for themselves or a minor. Managed by ConnectiveRx.
For: private insurance · source - Bridge or quick-start supply
Head Start of EOHILIA: a one-time free 30-day supply for commercially insured patients when their plan does not first grant access; the page says it lasts up to 3 months or until insurance approval, whichever comes first.
For: private insurance · source
Good to know: Read on eohilia.com/copay-savings on November 15, 2026. The copay line is open 24/7 except Christmas Day. The page does not mention Help at Hand or any free-drug program for uninsured patients.
Charity funds for Eosinophilic Esophagitis
- From a charity · TotalAssist (formerly PAN Foundation)Eosinophilic Esophagitis fundOpen
Pays for: Out-of-pocket costs for approved medications, up to $2,000 per year. Requires Medicare, Medicaid or TRICARE.
- From a charity · The Assistance FundEosinophilic Esophagitis fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
Every program and charity fund for Eosinophilic Esophagitis →
Access and eligibility
Approved for 12 weeks of treatment in adults and children 11 and older with eosinophilic esophagitis[1]. Safety and effectiveness have not been shown beyond 12 weeks or in children younger than 11[1]. Eohilia is not used by people allergic to budesonide and is not recommended with severe liver impairment[1]. The trials enrolled people whose EoE was still active after a proton pump inhibitor course, and most kept taking a proton pump inhibitor during the trials[1].
Source: EOHILIA Patient Support and Copay Program
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Clinical trial results
Eohilia was tested in 2 randomized, double-blind, placebo-controlled 12-week studies in people 11 and older whose EoE was still active after a course of a proton pump inhibitor[1]. In Study 1 (NCT02605837, 318 people), 53.1% on Eohilia reached histologic remission, 6 or fewer eosinophils per high-power field on biopsy, against 1.0% on placebo, and swallowing scores on the Dysphagia Symptom Questionnaire improved by 10.2 points against 6.5[1][5].
In Study 2 (NCT01642212, 92 people), remission was 38.0% against 2.4%, and swallowing scores improved by 14.5 points against 5.9[1][6]. In an extension where 48 people from Study 1 were re-randomized to keep taking Eohilia or switch to placebo for up to 36 more weeks, Eohilia did not show a statistically significant difference from placebo on eosinophil counts or swallowing symptoms[1].
Development history
Takeda says the medicine, then called TAK-721, entered its pipeline through its acquisition of Shire[4]. Its main trial was registered under the Shire study number SHP621-301[5]. On December 21, 2021, Takeda announced that the FDA had issued a complete response letter, saying the application could not be approved in its present form and recommending an additional clinical study[4].
The FDA approved Eohilia on February 9, 2024 under NDA 213976, with a labeling supplement approved on May 16, 2024[2]. Takeda announced the approval on February 12, 2024 and said the packets would be available by the end of that month[3]. The current label was revised in January 2025[1].
Explore Eosinophilic Esophagitis trials
Common questions about Budesonide oral suspension
▸What is Budesonide oral suspension (Eohilia)?
A thick, cherry-flavored liquid steroid swallowed from a packet twice a day for 12 weeks to treat eosinophilic esophagitis (EoE) in people 11 and older[1]. The FDA approved Eohilia on February 9, 2024[2], and Takeda described it as the first FDA-approved oral therapy for EoE[3]. Its label says it has not been shown to be safe and effective for longer than 12 weeks[1].
▸How does Budesonide oral suspension work?
In eosinophilic esophagitis, allergy-type immune cells called eosinophils build up in the lining of the esophagus, the tube that carries food to the stomach, which can make swallowing hard. Budesonide is a corticosteroid with a strong glucocorticoid effect and a weak mineralocorticoid effect, and its binding to the glucocorticoid receptor is about 200 times that of cortisol and 15 times that of prednisolone[1]. The label says the exact way corticosteroids work on inflammation in EoE is not known, and that they act against many of the cells and signals involved in allergic inflammation, including mast cells, eosinophils and histamine[1]. Eohilia is a thick suspension swallowed straight from the packet, and people are told not to eat or drink for 30 minutes afterward[1]. Budesonide is broken down by the liver enzyme CYP3A4, which is why drugs and grapefruit juice that block that enzyme can raise the amount reaching the bloodstream[1].
▸What are the side effects of Budesonide oral suspension?
Eohilia has no boxed warning[1]. Its label warns that, like other corticosteroids, it can cause signs of excess cortisol and suppress the adrenal glands, raise the risk of infection, slow growth in children, cause withdrawal symptoms in people switching from stronger whole-body steroids, and worsen conditions such as high blood pressure and diabetes[1]. Chickenpox and measles can be serious or fatal in people on steroids who are not immune, and the label says to avoid Eohilia with fungal infections, Strongyloides threadworm infection, cerebral malaria or herpes infection of the eye[1]. In the main 12-week trial of 213 people on Eohilia and 105 on placebo, side effects in at least 2% and more common than placebo were respiratory tract infections (13% against 11%), yeast infections of the mouth, throat or esophagus (8% against 2%), headache (5% against 2%), gastroenteritis (3% against 1%), throat irritation (3% against 2%), adrenal suppression (2% against 0) and erosive esophagitis (2% against 0)[1]. Erosive esophagitis was found in 4 of 213 people at the 12-week endoscopy, and all but 1 of them were also taking a proton pump inhibitor[1]. Since approval, anaphylaxis, raised pressure around the brain and mood swings have been reported with oral budesonide products[1].
▸How is Budesonide oral suspension taken?
The dose is 2mg, one 10mL packet, swallowed twice a day for 12 weeks[1]. The packet is shaken for at least 10 seconds, then squeezed from the bottom up directly into the mouth 2 to 3 times until empty, and the whole dose is swallowed[1]. Eohilia is not mixed with food or liquid. Nothing is eaten or drunk for 30 minutes afterward, then the mouth is rinsed with water and spat out without swallowing[1]. The label says to avoid grapefruit juice during treatment and to avoid CYP3A4 blockers such as ketoconazole, itraconazole, ritonavir, erythromycin and cyclosporine[1]. Eohilia is not recommended with severe liver impairment[1]. Each carton holds 60 packets, stored between 2°C and 25°C (36°F to 77°F) and never frozen[1].
▸Is Budesonide oral suspension FDA approved?
Yes. The FDA approved Eohilia on February 9, 2024 for 12 weeks of treatment in adults and children 11 and older with eosinophilic esophagitis.
Length: the label says it has not been shown to be safe and effective beyond 12 weeks.
Younger children: safety and effectiveness under age 11 have not been established.
Dose: one 2mg packet twice a day.
Source: Eohilia prescribing information
▸How do you take Eohilia?
One 2mg packet is squeezed straight into the mouth and swallowed, twice a day for 12 weeks[1].
Before: shake the packet for at least 10 seconds.
Do not: mix it with food or liquid.
After: no eating or drinking for 30 minutes, then rinse the mouth with water and spit it out.
Avoid: grapefruit juice during treatment.
Source: Eohilia prescribing information
▸How well does Eohilia work for EoE?
In the main 12-week trial, 53.1% on Eohilia reached histologic remission, 6 or fewer eosinophils per high-power field, against 1.0% on placebo[1].
Second trial: 38.0% against 2.4%.
Swallowing: scores improved by 10.2 points against 6.5 in the first trial and 14.5 against 5.9 in the second.
Longer use: in a 36-week extension, Eohilia did not show a statistically significant difference from placebo.
Source: Eohilia prescribing information
▸Why is Eohilia limited to 12 weeks?
The label says Eohilia has not been shown to be safe and effective for treating EoE for longer than 12 weeks[1].
Extension study: people who kept taking Eohilia for up to 36 more weeks did not do statistically better than those switched to placebo.
Steroid effects: the label lists adrenal suppression, infections and slower growth in children as risks.
After 12 weeks: the next step is a question for the gastroenterologist.
Source: Eohilia prescribing information
▸Is there a copay card for Eohilia?
Yes. Eligible commercially insured patients may pay as little as $0, with a maximum annual benefit of up to $5,000[7].
Not eligible: Medicare, Medicare Advantage, Medicaid, TRICARE or other government plans, and cash-paying patients.
Waiting on coverage: Head Start gives a one-time free 30-day supply when a commercial plan does not first approve Eohilia.
Phone: 1-866-861-1482, open 24/7 except Christmas Day.
Source: Eohilia copay program
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Takeda Pharmaceuticals America, Inc. via DailyMed · 2025-02-06. EOHILIA (BUDESONIDE) SUSPENSION. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56f2023a-69b2-4470-b4ad-af7ec1be527a
- U.S. Food and Drug Administration · 2024-02-09. Drugs@FDA: FDA-Approved Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213976
- Takeda · 2024-02-12. FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE). https://www.takeda.com/newsroom/newsreleases/2024/fda-approves-eohilia/
- Takeda · 2021-12-21. Takeda Receives Complete Response Letter from the US FDA for TAK-721. https://www.takeda.com/en-us/newsroom/news-releases/2021/takeda-receives-complete-response-letter-from-the-us-fda-for-tak-721/
- ClinicalTrials.gov. A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved. https://clinicaltrials.gov/study/NCT02605837
- ClinicalTrials.gov. OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension. https://clinicaltrials.gov/study/NCT01642212
- Takeda. Patient Support & Copay Card Program | EOHILIA™ (budesonide oral suspension). https://www.eohilia.com/copay-savings
- Sanofi-Aventis U.S. LLC via DailyMed · 2026-04-22. DUPIXENT (DUPILUMAB) INJECTION, SOLUTION. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780
- Gastroenterology · 2020-05. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis.. https://pubmed.ncbi.nlm.nih.gov/32359562/